New combo attack on brain tumors: electric fields, laser, and immunotherapy

NCT ID NCT06558214

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the safety and feasibility of combining three treatments—tumor-treating electric fields (Optune GIO), MRI-guided laser ablation (NeuroBlate), and the immunotherapy drug pembrolizumab (Keytruda)—in 20 adults with recurrent glioblastoma. Participants receive the triple combination, and researchers monitor for severe side effects and how well the treatment can be delivered. The goal is to see if this aggressive approach is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (Keytruda), Tumor Treating Fields (Optune GIO), and laser ablation (NeuroBlate)
What this could lead to: If successful, this combination could offer a new treatment option for recurrent glioblastoma, potentially improving survival and quality of life.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The triple therapy may cause serious side effects or fail to control tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

UF Health Shands Hospital
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.